Clinical Proteomics 2018

Dear Colleagues,

Technological advances in mass spectrometry instrumentation and in proteomics methods are moving the field of clinical proteomics towards the analysis of large numbers of patient samples in a reasonable time. State-of-the art protein quantification is achieved by applying chemical labelling technologies incorporating multiple isobaric tags (Isobaric tags for relative and absolute quantitation—iTRAQ, Tandem Mass Tags—TMT), by targeted methods (Multiple reaction monitoring/Selected reaction monitoring—MRM/SRM, SWATH), or by label free approaches (extracted ion chromatograms—XICs, spectral counts) in bottom–up proteomics combining tandem mass spectrometry with liquid chromatography or capillary electrophoresis for online peptide fractionation. This offers the opportunity to systematically study disease mechanisms using gel free approaches and improve our understanding on the role of proteins involved. These technologies enable biomarker discovery and biomarker validation studies with samples collected from human body fluids (e.g., blood, urine, saliva, and Cerebrospinal Fluid—CSF), from tissues, or from isolated cells. Current challenges for the utilisation of these technologies in the clinic, for prognosis, diagnosis, and for therapy monitoring, are (1) the large dynamic range of proteins present in body fluids, which is exceeding the capabilities of modern mass spectrometers with several orders of magnitude, and (2) reproducibility between laboratories, requiring standardization in the proteomic work flow encompassing standard operating procedures (SOPs) for sample collection, sample storage, sample processing techniques, MS data acquisition, and analysis methods.

In this Special Issue, we are looking forward to receive original clinical proteomics studies and review articles focussed on (1) the underlying mechanisms of disease pathways, (2) biomarker discovery studies using quantitative proteomics, and (3) mass spectrometry-based biomarker validation studies.

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Proteomes is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Clinical proteomics
• Human body fluids
• Disease mechanisms
• Biomarker discovery
• Biomarker validation

• Clinical Proteomics: Third Edition in Proteomes (2 articles)